Point: Justification for lynch syndrome screening among all patients with newly diagnosed colorectal cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 5, 2010, Pages 597-601

  Hampel, Heather ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Immunohistochemistry; Lynch syndrome; Microsatellite instability; Mismatch repair; Screening

Indexed keywords

B RAF KINASE; FLUOROURACIL; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ENDOMETRIUM CANCER; FAMILY HISTORY; GYNECOLOGIC CANCER; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK POPULATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METHYLATION; MICROSATELLITE INSTABILITY; NUCLEOTIDE REPEAT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77952965113     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0044     Document Type: Article

References (30)

1. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26:5783-5788.
2. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-1860.
3. Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27:4793-4797.
4. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002;94:1708-1712. (Pubitemid 34241108)
5. Renkonen-Sinisalo L, Butzow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007;120:821-824. (Pubitemid 46175402)
6. Rijcken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003;91:74-80. (Pubitemid 37188596)
7. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261-269. (Pubitemid 43113031)
8. Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481-1487. (Pubitemid 28226275)
9. Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000;18:2193-2200. (Pubitemid 30350210)
10. Samowitz WS, Curtin K, Lin HH, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 2001;121:830-838. (Pubitemid 32959394)
11. Baudhuin LM, Burgart LJ, Leontovich O, Thibodeau SN. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 2005;4:255-265. (Pubitemid 41242196)
12. Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-3460.
13. Kane MF, Loda M, Gaida GM, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-811. (Pubitemid 27097998)
14. Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42-65.
15. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618. (Pubitemid 46224239)
16. Des Guetz G, Schischmanoff O, Nicolas P, et al. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer 2009;45:1890-1896.
17. Burt RW, Barthel JS, Dunn KB, et al. NCCN clinical practice guidelines in oncology: colorectal cancer screening, version 1, 2010. Available at: http://www.nccn.org/professionals/physician- gls/PDF/colorectal-screening.pdf. Accessed March 18, 2010.
18. de Vos tot Nederveen Cappel WH, Nagengast FM, Griffioen G, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002;45:1588-1594.
19. Lynch HT, Harris RE, Lynch PM, et al. Role of heredity in multiple primary cancer. Cancer 1977;40(4 Suppl):1849-1854. (Pubitemid 8216956)
20. Mecklin JP, Jarvinen HJ. Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum 1986;29:160-164. (Pubitemid 16124067)
21. Jenkins MA, Dowty JG, Hopper JL, Sourhey MC. Molecular screening of all colorectal tumors diagnosed before age 50 years followed by genetic testing efficiently identifies Lynch syndrome cases. Int J Cancer 2009;124:x-i.
22. Schofield L, Watson N, Grieu F, et al. Population-based detection of Lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer 2009;124:1097-1102.
23. Balaguer F, Balmana J, Castellvi-Bel S, et al. Validation and extension of the PREMM 1,2 model in a population-based cohort of colorectal cancer patients. Gastroenterology 2008;134:39-46.
24. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986-1994.
25. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268. (Pubitemid 38256271)
26. Greenson JK, Huang SC, Herron C, et al. Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol 2009;33:126-133.
27. Jenkins MA, Hayashi S, O'Shea AM, et al. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007;133:48-56.
28. de la Chapelle A, Palomaki G, Hampel H. Identifying Lynch syndrome. Int J Cancer 2009;125:1492-1493.
29. Mahooti S, Hampel H, LaJeunesse J, et al. Amsterdam criteria, Bethesda guidelines, and histologic findings in 34 patients with hereditary nonpolyposis colorectal cancer [abstract]. Mod Pathol 2006;19(Suppl 113A):Abstract 513.
30. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed colorectal cancer patients. Genet Med 2010;12:93-104.